Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06911320 · ClinicalTrials.gov registry record · Phase 1
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
A Phase 1 study of Hepatic Impairment and Renal Impairment, sponsored by Atea Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT06911320: Recruiting Phase 1 study of Hepatic Impairment and Renal Impairment, sponsored by Atea Pharmaceuticals.
NCT06911320 is a Phase 1 study of Hepatic Impairment and Renal Impairment that is actively recruiting participants, run by Atea Pharmaceuticals. The registered enrollment target is 28 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (22% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06911320, a Phase 1 study of Hepatic Impairment and Renal Impairment, is actively recruiting participants, sponsored by Atea Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
Conditions Studied
Interventions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Study Locations (2)
Florida
- Atea Study Site - Orlando
- Atea Study Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
What NCT06911320 shows while recruiting
NCT06911320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (22% lower).
The record links to 3 conditions, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination is the first listed.
NCT06911320 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06911320 about?
NCT06911320 is a clinical study titled "Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function". To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
What is the current status of trial NCT06911320?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2025-04-09. Estimated completion is 2025-11.
What conditions does trial NCT06911320 study?
This clinical trial studies the following conditions: Hepatic Impairment, Renal Impairment, Healthy Volunteer Study.
What interventions are being tested in trial NCT06911320?
The interventions under investigation include: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination (DRUG).
Who is sponsoring clinical trial NCT06911320?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06911320 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06911320's enrollment target sits among peer trials
28 27th of 48 higher than 20 of 48 other Hepatic Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
-
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI